Arcus Biosciences, Inc. (RCUS) Financial Statements
Arcus Biosciences, Inc. (RCUS) reported trailing twelve-month revenue of $117.0M (down 55.3% year on year) and net income of -$460.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$475.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 21 Oct; these figures move once the 10-Q is filed.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.02 | 0.08 | 0.38 | 0.11 | 0.12 | 0.26 | 0.25 | 0.12 | |
| Gross profit | — | — | — | — | — | 0.24 | — | — | |
| Research & development | 0.08 | 0.16 | 0.26 | 0.29 | 0.34 | 0.45 | 0.52 | 0.50 | |
| Operating income | -0.09 | -0.12 | 0.05 | -0.28 | -0.34 | -0.33 | -0.39 | -0.49 | |
| Pre-tax income | — | — | 0.06 | -0.27 | -0.30 | -0.28 | -0.35 | -0.46 | |
| Income tax | — | — | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.08 | -0.12 | 0.05 | -0.27 | -0.31 | -0.28 | -0.35 | -0.46 | |
| Diluted EPS ($) | -1.93 | -2.24 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.64 | |
| Diluted shares (bn) | — | — | 0.074 | 0.072 | 0.074 | 0.090 | 0.107 | — |
USD billions · SEC XBRL
Arcus Biosciences, Inc. — questions
- What is Arcus Biosciences, Inc.'s revenue?
- $117.0M over the twelve months to 2026-06-30, down 55.3% year on year, from its 10-Q and 10-K filings.
- What is Arcus Biosciences, Inc.'s net income?
- -$460.0M over the twelve months to 2026-06-30.
- What is Arcus Biosciences, Inc.'s free cash flow?
- -$475.0M over the twelve months to 2026-06-30.
- What are Arcus Biosciences, Inc.'s diluted earnings per share?
- $-3.64 over the twelve months to 2026-06-30.
Every figure on this page comes from Arcus Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.